You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東瑞製藥(02348.HK):開展AK102在原發性高膽固醇血癥和混合型高脂血症III期臨牀研究
格隆匯 09-09 20:36

格隆匯9月9日丨東瑞製藥(02348.HK)公吿,公司獲康融東方吿知已獲准許啟動一項在原發性高膽固醇血癥和混合型高脂血症患者中評價Ebronucimab(AK102)長期療效和安全性的隨機、雙盲、安慰劑對照III期臨牀研究。

於2021年9月9日東瑞生物與中山康方簽訂了合資經營合同補充協議,以增加康融東方(由中山康方擁有65%及由東瑞生物擁有35%)的註冊資本,由人民幣1.43億元增至人民幣2.43億元。新增註冊資本人民幣1億元將由股東按照於康融東方的持股比例以現金方式不遲於2023年12月31日出資,即分別由東瑞生物支付人民幣3500萬元及由中山康方支付人民幣6500萬元.因此,康融東方的總投資額將由人民幣2.43億元增加至人民幣3.43億元。

根據上市規則第十四章,增加出資金額不構成公司須予披露交易。合營合同補充協議的條款由合資經營合同訂約方考慮康融東方的研究項目AK102進入III期臨牀及AK109進入II期臨牀試驗的資金需求而協定,能籍以提高集團於康融東方的投資價值。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account